Basic Information

Gene symbol MLANA Synonyms MART-1, MART1 Type of gene protein-coding
Description melan-A

GTO ID GTC0062
Trial ID NCT00706992
Disease Melanoma
Altered gene MART-1
Therapeutic/Target gene Target gene
TherapyTCR-T cell
Treatment MAGE-A1 F5 TCR-T cells
HLAHLA-A*02:01
PhasePhase2
Recruitment statusTerminated
TitleTransfer of Autologous T Cells Transduced With the Anti-MART-1 F5 T Cell Receptor in High Risk Melanoma
Year2008
CountryUnited States
Company sponsorNational Cancer Institute (NCI)
Other ID(s)080162|08-C-0162
Vector information
Vectorretrovirus
Transgene/Inserted geneanti-MART-1 F5 TCR genes

Clinical Result

Cohort1: TCR PBLs
Administration route infusion
Dosage 0.01~5E10 cells
Donor type autologous
Pts 8
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events
Cohort2: TCR PBLs_vaccine 1
Administration route infusion
Dosage 0.01~5E10 cells
Donor type autologous
Pts 8
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events
Cohort3: TCR PBLs_aldesleukin
Administration route infusion
Dosage 0.01~5E10 cells
Donor type autologous
Pts 9
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events
Cohort4: TCR PBLs_vaccine 1_aldesleukin
Administration route infusion
Dosage 0.01~5E10 cells
Donor type autologous
Pts 8
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events
Cohort5: TCR PBLs_vaccine 2_vaccine 3
Administration route infusion
Dosage 0.01~5E10 cells
Donor type autologous
Pts 6
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events
Cohort6: TCR PBLs_vaccine 2_aldesleukin_vaccine 3
Administration route infusion
Dosage 0.01~5E10 cells
Donor type autologous
Pts 5
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events
Cohort7: vaccine 2_vaccine 3
Administration route infusion
Donor type autologous
Pts 6
Age Adult, Older_Adult
Lymph depletion Yes
Adverse reactions No serious clinical adverse events

Relationship Graph

Overview of Knowledge Graph